Primo Brands Corporation (PRMB)
NYSE: PRMB · Real-Time Price · USD
24.00
-2.41 (-9.13%)
At close: Aug 7, 2025, 4:00 PM
24.26
+0.26 (1.08%)
Pre-market: Aug 8, 2025, 5:17 AM EDT
Longboard Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts that cover Longboard Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $40.7, which forecasts a 69.58% increase in the stock price over the next year. The lowest target is $38 and the highest is $48.
Price Target: $40.70 (+69.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Longboard Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 4 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $39 | Strong Buy | Maintains | $42 → $39 | +62.50% | Jul 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $38 | Buy | Initiates | $38 | +58.33% | Jul 2, 2025 |
| Barclays | Barclays | Buy Maintains $40 → $38 | Buy | Maintains | $40 → $38 | +58.33% | Jun 16, 2025 |
| Barclays | Barclays | Buy Initiates $40 | Buy | Initiates | $40 | +66.67% | Jun 4, 2025 |
| B of A Securities | B of A Securities | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +75.00% | May 28, 2025 |
Financial Forecast
Revenue This Year
7.10B
from 5.15B
Increased by 37.86%
Revenue Next Year
7.39B
from 7.10B
Increased by 4.08%
EPS This Year
1.60
from -0.07
EPS Next Year
1.87
from 1.60
Increased by 16.63%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 7.4B | 7.8B | 8.1B |
| Avg | 7.1B | 7.4B | 7.7B |
| Low | 6.8B | 7.0B | 7.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 44.0% | 9.6% | 9.5% |
| Avg | 37.9% | 4.1% | 3.9% |
| Low | 31.5% | -1.4% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.79 | 2.16 | 2.44 |
| Avg | 1.60 | 1.87 | 2.14 |
| Low | 1.42 | 1.62 | 1.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 35.2% | 30.6% |
| Avg | - | 16.6% | 14.9% |
| Low | - | 1.1% | 6.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.